OncoMatch/Clinical Trials/NCT06044506
Autologous Natural Killer Cell Therapy for Hepatocellular Carcinoma
Is NCT06044506 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Autologous Natural Killer Cell Therapy and Clinimacs Plus for hepatocellular carcinoma.
Treatment: Autologous Natural Killer Cell Therapy · Clinimacs Plus — This study represents a phase I clinical trial that utilizes natural killer (NK) cell therapy for patients diagnosed with liver cancer, specifically those classified as Child-Pugh A and falling within the Barcelona Clinic Liver Cancer (BCLC) stages B or C. The expected results include determining the suitable treatment dosage, identifying any resulting side effects, and calculating the average duration of progression-free survival. The target group for the study consists of all individuals diagnosed with liver cancer. At the same time, the practical sample consists of those who received medical care for liver cancer at Cipto Mangunkusumo Hospital (RSCM) between May and December 2022. The chosen research sample comprises liver cancer patients who fulfill the predetermined participation criteria. The necessary sample size for discerning appropriate treatment dosages and the occurrence rate of potential side effects shall consist of 2-3 liver cancer patients who are administered autologous NK cells. The process for isolating these NK cells adheres to the guidelines established by Miltenyi Biotec.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage BCLC B, BCLC C
Demographics
Prior therapy
Cannot have received: stem cell transplant
Lab requirements
Blood counts
platelet count ≥ 80,000/µl; white blood cell count ≥ 3000/µl; neutrophil count ≥ 2000; hemoglobin ≥ 9 mg/dl; international normalized ratio (inr) 0.8-1.5
Kidney function
serum creatinine < 1.3, serum urea < 10
Liver function
bilirubin < 2, sgot and sgpt < 60 u/l
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06044506 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior stem cell transplant disqualifies patients from enrollment.
What disease stage is eligible?
Stage BCLC B or BCLC C is required.
Is there an age limit?
Yes. Patients must be 60 years or younger and at least 20 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages